Novartis Coverage Initiated by Analysts at UBS AG (NVS)
Investment analysts at UBS AG started coverage on shares of Novartis (NYSE:NVS) in a note issued to investors on Thursday, Analyst Ratings Network.com reports. The firm set a “buy” rating on the stock.
NVS has been the subject of a number of other recent research reports. Analysts at Jefferies Group downgraded shares of Novartis from a “buy” rating to a “hold” rating in a research note to investors on Thursday. Separately, analysts at Natixis upgraded shares of Novartis from a “neutral” rating to a “buy” rating in a research note to investors on Monday, November 25th. Finally, analysts at Leerink Swann raised their price target on shares of Novartis from $80.00 to $83.00 in a research note to investors on Wednesday, October 23rd. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and six have assigned a buy rating to the company. Novartis has a consensus rating of “Buy” and a consensus target price of $82.33.
Novartis (NYSE:NVS) traded up 0.48% on Thursday, hitting $80.09. 851,230 shares of the company’s stock traded hands. Novartis has a one year low of $64.52 and a one year high of $80.55. The stock has a 50-day moving average of $78.64 and a 200-day moving average of $75.61. The company has a market cap of $195.0 billion and a P/E ratio of 21.03.
Novartis (NYSE:NVS) last posted its quarterly earnings results on Tuesday, October 22nd. The company reported $1.26 earnings per share for the quarter, missing the analysts’ consensus estimate of $1.31 by $0.05. The company had revenue of $14.34 billion for the quarter, compared to the consensus estimate of $14.28 billion. During the same quarter last year, the company posted $1.34 earnings per share. Novartis’s revenue was up 3.8% compared to the same quarter last year. Analysts expect that Novartis will post $5.14 EPS for the current fiscal year.
Novartis AG is a Switzerland-based holding that, through its subsidiaries, is engaged in the research, development, manufacture and marketing of healthcare products.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.